16Feb 2025
MEK Inhibitors Show Higher Efficacy in MAPK-ERK Mutated Erdheim-Chester Disease

MEK Inhibitors Show Higher Efficacy in MAPK-ERK Mutated Erdheim-Chester Disease

A study on 20 Erdheim-Chester disease (ECD) patients treated with MEK inhibitors (MEKi) found an 80% overall response rate (ORR). MAPK-ERK mutated cases had significantly higher ORR (93.3% vs. 40%) and prolonged progression-free survival. Non-responders with CSF1R and FLT3::MEF2C mutations benefited from targeted inhibitors, highlighting the need for mutation-based treatment strategies.

  • #oncology

Like

Save

Share